All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 16th 2025

SH-110 received orphan drug designation from the FDA for the treatment of patients with glioma.

FDA’s Published CRLs Deliver Insight Into the Drug Approval Process

July 16th 2025

Dive into each of the oncology-related CRLs that were recently released by the FDA, as well as relevant subsequent FDA decisions.

Classification Advances Guide Research and Precision Therapy in Non–Clear Cell RCC

July 16th 2025

Joseph Vento, MD, discusses how WHO updates and molecular profiling are shaping trial design and targeted treatment in non–clear cell RCC.

Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic

July 16th 2025

Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.

Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma

July 15th 2025

Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis

July 15th 2025

Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.

Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC, While Radium-223 Sequencing Requires Further Clarification

July 15th 2025

Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.

Common Medication for Lung Cancer Symptoms Found to Limit Effectiveness of Cancer Treatment

July 15th 2025

High doses of corticosteroids are likely the most significant factor in why some immunotherapies don’t work.

Tambiciclib Plus Azacitidine and Venetoclax Elicits Robust Antitumor Activity in R/R AML

July 15th 2025

Tambiciclib plus azacitidine and venetoclax generated favorable ORR, OS, and safety outcomes in patients with relapsed/refractory acute myeloid leukemia.

Early Safety Data Show Tolerability of Apalutamide Plus Carotuximab in Metastatic CRPC

July 15th 2025

Apalutamide plus carotuximab has been demonstrated to be well tolerated in patients with metastatic castration-resistant prostate cancer

Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma

July 15th 2025

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

New Approaches Combat GVHD and Improve Transplantation Outcomes in Hematologic Malignancies

July 15th 2025

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

ELM-2 Data Display Long-Term Efficacy and Safety of Odronextamab in R/R Follicular Lymphoma

July 15th 2025

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

FELIX Analysis Highlights Factors Associated With Sustained Remission With Obe-Cel in R/R Acute Lymphoblastic Leukemia

July 14th 2025

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Molecular Insights Guide First-Line and Post-Transplant Strategies in AML

July 14th 2025

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Relacorilant Plus Nab-Paclitaxel Provides PFS Benefit in Platinum-Resistant Ovarian Cancer

July 14th 2025

Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from the ROSELLA trial and the future of relacorilant in platinum-resistant ovarian cancer.

Mayo Clinic Researchers Link CAR-T Cell Aging to Cancer Relapse

July 14th 2025

Mayo Clinic researchers have discovered a key reason some patients with cancer relapse after receiving CAR T-cell therapy.

FDA Receives NDA for Relacorilant in Platinum-Resistant Ovarian Cancer

July 14th 2025

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

July 14th 2025

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

Regorafenib Plus Trifluridine/Tipiracil Shows Early Efficacy in Refractory Metastatic Colorectal Cancer

July 14th 2025

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.